B-F1RST enrolled patients with immunotherapy-naive stage IIIB–IVB NSCLC, regardless of PD-L1 status, excluding those with EGFR mutations or ALK alterations (Supplementary Methods). This evidence concerns the gene ALK and non-small cell lung carcinoma.